The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the duration of application of halobetasol
propionate 0.05% ointment to be used in a definitive study of bioequivalence of to
formulations of this ointment.
Part A: To validate vasoconstrictor assay precision.
Part B: To evaluate the dose response vasoconstriction profile of Ultravate® 0.05% ointment
at different dose durations over a short period of time (0.17 - 4 hrs).